<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">4418</id>
  <title>T3D4364</title>
  <common-name>L-Isoleucine</common-name>
  <description>L-Isoleucine is one of the essential amino acids that cannot be made by the body and is known for its ability to help endurance and assist in the repair and rebuilding of muscle. This amino acid is important to body builders as it helps boost energy and helps the body recover from training.  L-Isoleucine is also classified as a branched-chain amino acid (BCAA). It helps promote muscle recovery after exercise. Isoleucine is actually broken down for energy within the muscle tissue.  It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.</description>
  <cas>73-32-5</cas>
  <pubchem-id>6306</pubchem-id>
  <chemical-formula>C6H13NO2</chemical-formula>
  <weight>131.17</weight>
  <appearance>White powder.</appearance>
  <melting-point>285.5 dec°C</melting-point>
  <boiling-point></boiling-point>
  <density nil="true"/>
  <solubility>3.44E+004 mg/L (at 25°C)</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Absorbed from the small intestine by a sodium-dependent active-transport process</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>(Applies to Valine, Leucine and Isoleucine) &lt;br/&gt;This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. &lt;br/&gt;The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. &lt;br/&gt;There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS.</mechanism-of-toxicity>
  <metabolism>Hepatic</metabolism>
  <toxicity nil="true"/>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>The branched-chain amino acids may have antihepatic encephalopathy activity in some. They may also have anticatabolic and antitardive dyskinesia activity.</use-source>
  <min-risk-level nil="true"/>
  <health-effects nil="true"/>
  <symptoms>Symptoms of hypoglycemia</symptoms>
  <treatment nil="true"/>
  <created-at type="dateTime">2014-08-29T06:35:06Z</created-at>
  <updated-at type="dateTime">2026-04-17T18:55:30Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Ile</wikipedia>
  <uniprot-id nil="true"/>
  <kegg-compound-id>C00407</kegg-compound-id>
  <omim-id nil="true"/>
  <chebi-id>17191</chebi-id>
  <biocyc-id>ILE</biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id nil="true"/>
  <drugbank-id>DB00167</drugbank-id>
  <pdb-id>ILE</pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>CC[C@H](C)[C@H](N)C(O)=O</moldb-smiles>
  <moldb-formula>C6H13NO2</moldb-formula>
  <moldb-inchi>InChI=1S/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1</moldb-inchi>
  <moldb-inchikey>AGPKZVBTJJNPAG-WHFBIAKZSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">131.1729</moldb-average-mass>
  <moldb-mono-mass type="decimal">131.094628665</moldb-mono-mass>
  <origin>Endogenous</origin>
  <state>Solid</state>
  <logp>-1.7</logp>
  <hmdb-id>HMDB00172</hmdb-id>
  <chembl-id>CHEMBL1233584</chembl-id>
  <chemspider-id>6067</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference>&lt;p&gt;Nelli I. Zhdanova, Tatyana V. Leonova, Ljudmila F. Kozyreva, &amp;#8220;Method of producing L-isoleucine using Brevibacterium flavum.&amp;#8221; U.S. Patent US4237228, issued February, 1962.&lt;/p&gt;</synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM003324</chemdb-id>
  <dsstox-id>DTXSID1047441</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00009745</susdat-id>
  <iupac>(2S,3S)-2-amino-3-methylpentanoic acid</iupac>
</compound>
